Management ChangeJul 17, 2026, 04:21 PM
NovaBay Appoints Henry Blynn as Chief Operating Officer
AI Summary
NovaBay Pharmaceuticals, Inc. appointed Henry Blynn as its Chief Operating Officer, effective July 15, 2026. Mr. Blynn will receive an annual salary of $300,000 and is eligible for an annual cash bonus targeting 50% of his base salary. He was also granted 1,400,000 time-based Restricted Stock Units (RSUs) which will vest in three equal installments over three years. The employment agreement includes severance provisions, which increase to 12 months of salary and benefits if termination occurs within 12 months of a change in control.
Key Highlights
- Henry Blynn appointed Chief Operating Officer of NovaBay Pharmaceuticals, effective July 15, 2026.
- Annual base salary set at $300,000.
- Eligible for an annual cash bonus with a target of 50% of his base salary.
- Severance benefits include 6 months of base salary and health benefits upon qualifying termination.
- Severance increases to 12 months of salary and benefits if termination follows a change in control.
- Granted 1,400,000 time-based Restricted Stock Units (RSUs).
- RSUs vest in equal one-third installments on February 16, 2027, January 16, 2028, and January 16, 2029.
- priority
Price Impact
More from NBY